Trial · NCT04782687
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT04782687, Phase 2, Active not recruiting, US Oncology Research
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma. Trials, record NCT04782687. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04782687
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
- NCT number
- NCT04782687
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 73 participants, actual
- Lead sponsor
- US Oncology Research
- Conditions
- Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
- Interventions
- Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
- First posted
- 2021-03-04
- Last updated
- 2025-01-16
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate (CR) | 6 months | percentage of patients who had complete response. Complete response is when patients achieve a negative immunofixation on the serum and urine and who also have an appearance of a soft tissue plasmacytomas and achieve less than or equal to 5 percent (%) plasma cells in the bone marrow. |
| Primary | Stringent Complete Response Rate (sCR) | 6 months | percentage of patients who had stringent complete response. Patients with a stringent complete response in addition to the criteria that is required to have a complete response are required to have a normal free light chain ratio in the serum and absence of clonal cells in the bone marrow determined by either immunofluorescence or immunohistochemistry. |
| Primary | Safety of Selinexor plus DRd | 3 years | frequency (incidence rate) of adverse effects |
| Secondary | Objective Response Rate (ORR) | 3 years | percentage of patients who had either CR or sCR or very good partial response (VGPR) or partial response (PR). |
| Secondary | Time to Next Treatment (TTNT) | 3 years | the median interval between the date of study treatment initiation and the date of start of a new treatment |
| Secondary | Duration of Response | 3 years | the median time from first documented evidence of PR, CR,or sCR to date of progression or death or last date of contact for patients who did not progress or die |
| Secondary | Progression-Free Survival (PFS) | 3 years | the median time from randomization until the date of disease progression or death (by any cause in the absence of progression), regardless of whether the subject withdraws from the assigned study treatment |
| Secondary | Overall Survival (OS) | 3 years | the median time from randomization until death due to any cause or date of last contact for alive patients |
| Secondary | Minimal Residual Disease (MRD) | 3 years | number of patients who had CR or sCR and had: absence of phenotypically abnormal clonal plasma cells from bone marrow aspirates using Adaptive Technologies NGS Platform |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04782687
GET https://conductscience.org/api/trials/v1/NCT04782687/registered